Stiff Person Syndrome: Diagnosis and Management
Stiff person syndrome (SPS) is a rare, progressive autoimmune disorder of the central nervous system characterized by fluctuating muscular rigidity of the axial and proximal limb muscles with superimposed painful spasms triggered by sensory or emotional stimuli. First described by Moersch and Woltman in 1956 as "stiff-man syndrome," it is now recognized as the prototypical autoimmune neuronal hyperexcitability disorder within the broader stiff person spectrum disorder (SPSD). This article synthesizes evidence from the Dalakas 2022 and 2024 reviews (Neurotherapeutics; Nature Reviews Neurology), the Chia et al. 2023 Mayo Clinic diagnostic criteria study (Annals of Clinical and Translational Neurology), and the most recent treatment data including the KYSA-8 CAR T-cell trial (2025).
Bottom Line
- Rare autoimmune disorder — prevalence ~1–2 per million (traditional estimate), though recent population-based data suggest it may be more common (~2 per 100,000); female predominance (60–70%); typical onset ages 30–60
- Core features: Progressive axial rigidity, lumbar hyperlordosis, painful episodic spasms triggered by emotional, tactile, or auditory stimuli, co-contraction of agonist/antagonist muscles, exaggerated startle
- Pathophysiology: Autoimmune impairment of GABAergic inhibition; anti-GAD65 antibodies in ~80% (very high titers >2,000 IU/mL); anti-amphiphysin (paraneoplastic, ~5%); anti-glycine receptor (PERM variant)
- Diagnosis: Dalakas criteria (axial stiffness, spasms, EMG continuous motor unit activity, high-titer GAD65 Ab, absence of alternative diagnosis); CSF shows intrathecal GAD65 synthesis and oligoclonal bands in ~67%
- Treatment: Symptomatic (benzodiazepines, baclofen, gabapentin) combined with immunotherapy (IVIg has strongest evidence — Dalakas 2001 NEJM trial); rituximab for refractory cases; CAR T-cell therapy (miv-cel) showing breakthrough results in 2025
- Autoimmune comorbidity: Type 1 diabetes (~35%), autoimmune thyroiditis, pernicious anemia, vitiligo; paraneoplastic variant associated with breast cancer and amphiphysin antibodies
Classification and Spectrum
SPS exists on a clinical spectrum now collectively termed stiff person spectrum disorder (SPSD). The spectrum encompasses several phenotypic variants based on the distribution and severity of symptoms and associated antibody profiles.
| Variant | Clinical Features | Associated Antibodies | Prognosis |
|---|---|---|---|
| Classic SPS | Progressive axial rigidity (trunk, paraspinal muscles), lumbar hyperlordosis, episodic painful spasms, exaggerated startle; symptoms symmetric; no brainstem or cerebellar signs | Anti-GAD65 (80–85%); high titers (>2,000 IU/mL, often >10,000 IU/mL) | Chronic progressive; responds to IVIg and GABA-enhancing drugs in majority |
| Stiff-Limb Syndrome (SLS) | Stiffness and spasms predominantly affecting one or more limbs (often distal); may be asymmetric; axial involvement less prominent; can progress to classic SPS | Anti-GAD65 (variable titers); occasionally anti-amphiphysin | Generally more focal; some patients remain stable, others evolve to classic SPS |
| SPS-Plus | Classic SPS features with additional neurological signs: cerebellar ataxia, brainstem dysfunction, eye movement abnormalities, epilepsy, or cognitive impairment | Anti-GAD65 (high titers); may overlap with other GAD-spectrum disorders | More severe disability; may indicate broader CNS autoimmunity |
| PERM (Progressive Encephalomyelitis with Rigidity and Myoclonus) | Severe variant: encephalopathy, rigidity and spasms, prominent myoclonus, brainstem signs (oculomotor dysfunction, dysphagia), autonomic instability, hyperekplexia, seizures; can be rapidly progressive and fatal | Anti-GlyR (~50% of PERM cases); anti-GAD65; anti-DPPX; anti-amphiphysin; may be dual-positive (GlyR + GAD65) | Most severe on the spectrum; life-threatening dysautonomia; some respond to aggressive immunotherapy |
| Paraneoplastic SPS | Classic SPS or SLS features in the context of underlying malignancy; may present before cancer diagnosis; can involve upper and lower extremities prominently | Anti-amphiphysin (~5% of all SPS cases); less commonly anti-GAD65 with cancer | Dependent on cancer treatment; may improve with tumor resection; breast cancer and small-cell lung cancer most common |
Epidemiology
- Traditional prevalence: ~1–2 per million population (incidence ~1 per million per year)
- Updated population-based data (2024): A Colorado-based health system study found a prevalence of 2.11 per 100,000 and average yearly incidence of 0.35 per 100,000 person-years (2012–2022), suggesting SPS may be significantly underdiagnosed
- Japanese nationwide survey (2023): Estimated prevalence of 0.11 per 100,000 for GAD65-positive SPS; 30 confirmed cases identified; median age at onset 51 years; 76% female
- Sex distribution: Female predominance — 60–76% of cases across studies
- Age of onset: Most commonly 30–60 years, with peak in the 4th–5th decade; range from 20 to 83 years
- No clear racial or ethnic predilection
- Diagnostic delay: Average 6–7 years from symptom onset to diagnosis; the Chia et al. 2023 Mayo Clinic study found that misdiagnosis (72% of referrals) was threefold more common than confirmed SPSD, with functional neurological disorder and pain syndromes being the most common alternative diagnoses
Pathophysiology
SPS results from autoimmune disruption of GABAergic inhibitory neurotransmission in the central nervous system. The loss of GABA-mediated inhibition leads to neuronal hyperexcitability, resulting in continuous involuntary motor unit firing and heightened responses to sensory stimuli.
Autoantibody Profiles
| Antibody | Target | Frequency in SPSD | Mechanism | Clinical Associations |
|---|---|---|---|---|
| Anti-GAD65 | Glutamic acid decarboxylase 65 kDa (intracellular enzyme catalyzing glutamate → GABA conversion) | ~80–85% of classic SPS; 98% in some series | Reduces GABA synthesis; intrathecally synthesized (CSF titers often exceed serum when corrected for IgG index); pathogenic role debated — intracellular target suggests T-cell or complement-mediated mechanisms may contribute | Classic SPS; SPS-plus; also found at lower titers in type 1 diabetes (2–4%), cerebellar ataxia, autoimmune epilepsy, limbic encephalitis |
| Anti-amphiphysin | Amphiphysin (synaptic vesicle endocytosis protein, intracellular) | ~5% of SPS cases | Disrupts synaptic vesicle recycling; reduces GABA release at presynaptic terminals | Paraneoplastic SPS — strongly associated with breast adenocarcinoma (~43% of amphiphysin-positive cases) and small-cell lung cancer (~57%); thymoma; Hodgkin lymphoma |
| Anti-GlyR (glycine receptor α1 subunit) | Glycine receptor (cell-surface inhibitory receptor) | ~10% of SPSD; ~50% of PERM cases | Directly blocks glycine-mediated inhibition (cell-surface antibody — pathogenic mechanism more clearly established); complement-mediated internalization of receptors | PERM; hyperekplexia; brainstem encephalitis; some overlap with optic neuritis; may coexist with anti-GAD65 |
| Anti-DPPX | Dipeptidyl-peptidase-like protein 6 (cell-surface Kv4.2 channel auxiliary subunit) | Rare | Alters Kv4.2 potassium channel function; affects neuronal excitability | PERM; encephalitis with hyperekplexia, diarrhea (prodromal), weight loss; may respond to immunotherapy |
| Seronegative | No identified antibody | 5–15% of clinical SPSD | Unknown; may involve undiscovered antibodies or non-humoral immune mechanisms | Diagnosis relies on clinical + EMG criteria; generally less responsive to immunotherapy |
Key Pathophysiological Concepts
- Intrathecal antibody production: GAD65 antibodies are synthesized within the CNS by B cells that have crossed the blood-brain barrier; intrathecal GAD-IgG synthesis index is elevated; CSF GAD65 titers may be higher than serum when corrected for total IgG
- Titer significance: SPS-associated GAD65 titers are characteristically very high (>2,000 IU/mL, typically >10,000 IU/mL); low-titer GAD65 positivity (<20 nmol/L by Mayo assay) is common in type 1 diabetes and does not indicate SPS
- GAD65 vs GAD67: GAD65 is the predominant isoform targeted in SPS; anti-GAD67 antibodies are found in ~60% and typically coexist with anti-GAD65
- GABA pathway disruption: Reduced GABAergic inhibition in brainstem and spinal cord motor circuits leads to continuous motor neuron firing, co-contraction of agonists and antagonists, and lowered threshold for startle and spasm responses
- Pathogenic controversy: Because GAD65 is intracellular, how antibodies access their target remains debated; proposed mechanisms include: antibody uptake during synaptic vesicle cycling, complement activation, cytotoxic T-cell mediation, and the possibility that GAD65 antibodies are an epiphenomenon with the true pathogenic target being unidentified
Clinical Features
Core Motor Symptoms
- Axial rigidity: Progressive stiffness affecting paraspinal, abdominal, and proximal limb muscles; initially episodic, becoming persistent; board-like rigidity of the abdomen is characteristic
- Lumbar hyperlordosis: Present in ~87% of classic SPS; results from continuous contraction of paraspinal extensors; may produce a characteristic fixed posture
- Episodic spasms: Painful, often severe muscle spasms superimposed on background rigidity; triggered by:
- Emotional stress and anxiety (task-specific phobias are common)
- Tactile stimulation (touch, unexpected contact)
- Auditory stimuli (sudden loud noises)
- Voluntary movement attempts
- Co-contraction of agonist and antagonist muscles: Simultaneous involuntary activation of opposing muscle groups (a hallmark feature detectable on EMG)
- Exaggerated startle response (hyperekplexia): Present in ~81% of confirmed SPSD (Chia et al. 2023); disproportionate whole-body startle to unexpected stimuli
Gait and Mobility
- Stiff, slow, cautious gait — "tin soldier" or robotic appearance due to restricted trunk rotation
- Unexplained falls: Reported in 76% of SPSD patients (vs. 46% in misdiagnosed patients); spasms may cause sudden loss of balance
- Task-specific phobias: Fear of crossing open spaces (agoraphobia-like), walking in crowds, or being startled; these are not primary psychiatric symptoms but stem from learned fear of triggering spasms and falls
Autonomic Dysfunction
- Episodes of tachycardia, diaphoresis, hypertension
- Especially prominent in PERM variant — can be life-threatening
- Pupillary abnormalities, temperature dysregulation
Psychiatric and Cognitive Features
- Anxiety disorder (often prominent, may dominate early presentation)
- Depression (reactive to disability and chronic pain)
- Cognitive impairment in SPS-plus and PERM variants
Diagnostic Approach
Dalakas Diagnostic Criteria (Revised 2009)
The most widely accepted diagnostic framework requires all five of the following:
Dalakas Criteria for Classic SPS
- Stiffness of axial muscles — particularly abdominal and thoracolumbar paraspinals, leading to fixed hyperlordosis
- Superimposed painful spasms triggered by tactile, auditory, or emotional stimuli
- EMG evidence of continuous motor unit activity in agonist and antagonist muscles simultaneously
- Absence of other neurological findings that might suggest an alternative diagnosis
- Positive serological testing for GAD65, amphiphysin, or GlyR antibodies (confirmed by immunocytochemistry, Western blot, or radioimmunoassay)
Chia et al. 2023 Mayo Clinic Suggested Criteria
In a study of 173 referrals, only 28% (48/173) were confirmed SPSD, highlighting the high misdiagnosis rate. Key distinguishing features of confirmed SPSD vs. mimics included:
| Feature | Confirmed SPSD | Non-SPSD (Mimics) | p-value |
|---|---|---|---|
| Exaggerated startle | 81% | 56% | 0.02 |
| Unexplained falls | 76% | 46% | 0.001 |
| Other autoimmune comorbidity | 50% | 27% | 0.005 |
| Electrodiagnostic abnormalities | 74% | 17% | <0.001 |
| Improvement with benzodiazepines | 51% | 16% | <0.001 |
| Improvement with immunotherapy | 45% | 13% | <0.001 |
The suggested criteria require: (1) clinical SPSD manifestations confirmed by an autoimmune neurologist, (2) seropositivity for high-titer GAD65-IgG (>20 nmol/L by Mayo assay), GlyR-IgG, or amphiphysin-IgG, and/or (3) confirmatory electrodiagnostic studies (essential if seronegative).
Diagnostic Investigations
| Test | SPS Findings | Key Notes |
|---|---|---|
| Serum anti-GAD65 antibodies | Very high titers: typically >2,000 IU/mL (ELISA) or >20 nmol/L (Mayo RIA); often >10,000 IU/mL | Low-titer GAD65 positivity is nonspecific (found in 2–4% of type 1 diabetes patients); high-titer GAD65 is the strongest independent diagnostic predictor; 98% sensitivity in classic SPS in some series |
| CSF analysis | GAD65 antibodies in CSF (100% sensitivity in classic SPS in one series); oligoclonal bands in ~67%; elevated IgG index; intrathecal GAD-IgG synthesis | CSF GAD65 positivity adds diagnostic specificity; intrathecal synthesis confirms CNS-specific autoimmune process; normal protein and cell count typical |
| EMG | Continuous motor unit activity (CMUA) at rest in paraspinal and abdominal muscles; normal motor unit morphology; simultaneous activation of agonist and antagonist muscles; activity abolished by diazepam or general anesthesia | CMUA is a hallmark finding (>90% sensitivity in classic SPS); not pathognomonic but highly supportive; best detected in paraspinal muscles; surface EMG may miss subtle findings |
| Anti-amphiphysin antibodies | Positive in ~5% of SPS cases | Strongly suggests paraneoplastic etiology; mandates comprehensive cancer screening (CT chest/abdomen/pelvis, mammography, PET/CT) |
| Anti-GlyR antibodies | Positive in ~50% of PERM; ~10% of broader SPSD | Cell-surface antibody with more direct pathogenic mechanism; better immunotherapy response potential; test in serum and CSF |
| MRI brain and spine | Typically normal in classic SPS | Used primarily to exclude alternative diagnoses (myelopathy, demyelinating disease, structural lesion); may show subtle T2 changes in SPS-plus or PERM |
Diagnostic Pitfalls
- Misdiagnosis is common: 72% of referrals to a specialized center were non-SPSD (Chia et al. 2023); most common mimics include functional neurological disorder, fibromyalgia, ankylosing spondylitis, and primary anxiety disorders
- Low-titer GAD65 is not SPS: Patients with type 1 diabetes or other autoimmune conditions may have low-titer GAD65 positivity without SPS; the diagnosis requires high titers in the appropriate clinical context
- Seronegative SPSD exists: 5–15% of clinically definite SPSD are seronegative; EMG confirmation is essential in these cases
- Always screen for malignancy when amphiphysin antibodies are detected or when presentation is atypical
Associated Conditions
SPS is strongly associated with other autoimmune conditions, reflecting a shared susceptibility to organ-specific autoimmunity.
| Associated Condition | Frequency in SPS | Key Details |
|---|---|---|
| Type 1 diabetes mellitus | ~30–35% (some reports up to 60%) | Most common autoimmune comorbidity; both conditions share GAD65 as an autoantibody target; diabetes titers are characteristically lower than SPS titers |
| Autoimmune thyroid disease | ~10–20% | Hashimoto thyroiditis or Graves disease; thyroid antibodies should be screened routinely |
| Pernicious anemia | ~5–10% | Anti-intrinsic factor or anti-parietal cell antibodies; check B12 levels |
| Vitiligo | Occasional | Part of the polyautoimmune cluster |
| Autoimmune polyendocrine syndrome type 2 | Recognized overlap | Combination of type 1 diabetes, thyroid disease, and other organ-specific autoimmunity in the context of SPS |
| Epilepsy / cerebellar ataxia | Part of GAD-spectrum | GAD65 antibodies can cause autoimmune epilepsy and cerebellar ataxia as separate or overlapping phenotypes |
Paraneoplastic Associations
- Overall frequency: Paraneoplastic SPS accounts for 1–10% of all SPS cases
- Amphiphysin-positive SPS:
- Breast adenocarcinoma (~43% of amphiphysin-positive cases in a Mayo Clinic series)
- Small-cell lung cancer (~57% in the same series)
- Less commonly: colon carcinoma, thymoma, Hodgkin lymphoma
- Cancer screening: Mandatory when amphiphysin antibodies are detected; includes CT chest/abdomen/pelvis, mammography, and consideration of PET/CT; repeat screening at 6–12 month intervals for 2–3 years if initial screening is negative
- Treatment of paraneoplastic SPS: Tumor-directed therapy (surgery, chemotherapy, radiation) is essential; neurological symptoms may improve with successful oncologic treatment
Treatment
Treatment follows a dual strategy: (1) symptomatic therapy with GABA-enhancing agents to reduce stiffness and spasms, and (2) immunotherapy to target the underlying autoimmune process. The standard approach begins with GABA-enhancing drugs and escalates to immunotherapy if symptoms are not adequately controlled within 2–3 months.
Symptomatic Therapy (GABA-Enhancing Agents)
| Agent | Mechanism | Dosing | Key Notes |
|---|---|---|---|
| Diazepam | GABAA receptor agonist (benzodiazepine) | Start 2 mg TID; titrate gradually; typical effective dose 20–60 mg/day; some patients require up to 100–120 mg/day in divided doses | First-line symptomatic agent; also reduces anxiety; doses required in SPS are much higher than typical anxiolytic doses; tolerance may develop requiring dose escalation; abrupt withdrawal can precipitate life-threatening spasms and status spasticus |
| Clonazepam | GABAA receptor agonist | 0.5–6 mg/day in divided doses | Alternative to diazepam if not tolerated; longer half-life; effective for myoclonus component; similar sedation and dependency risk |
| Baclofen (oral) | GABAB receptor agonist | Start 10 mg daily; titrate slowly to 30–80 mg/day in 3 divided doses | Preferred first choice among GABA-enhancing agents by some experts (Dalakas); does not require endogenous GABA for effect; combine with low-dose benzodiazepine; cognitive side effects at high doses |
| Baclofen (intrathecal) | GABAB receptor agonist (intrathecal pump) | 50–800 μg/day via implanted pump | For severe, refractory spasticity; avoids systemic cognitive side effects; requires surgical pump placement; risk of withdrawal syndrome with pump failure |
| Gabapentin | Modulates voltage-gated calcium channels; may enhance GABA | 300–3,600 mg/day in divided doses | Useful adjunct; particularly helpful for neuropathic pain component; combined with baclofen and low-dose benzodiazepine |
| Pregabalin | Similar to gabapentin | 75–600 mg/day | Alternative to gabapentin; may be better tolerated in some patients |
| Dantrolene, tizanidine, levetiracetam, vigabatrin | Various (muscle relaxant, α2-agonist, SV2A modulation, GABA transaminase inhibitor) | Standard doses | Second- and third-line adjunctive agents; limited evidence in SPS; vigabatrin (irreversible GABA-T inhibitor) has theoretical rationale but visual field defect risk limits use |
Practical Symptomatic Treatment Algorithm (Dalakas 2022)
- Step 1: Oral baclofen (first choice) + gabapentin + low-dose diazepam
- Step 2: If inadequate after 2–3 months, escalate doses; consider alternative agents
- Step 3: If still insufficient, proceed to immunotherapy while continuing symptomatic agents
- Severe/refractory spasticity: Consider intrathecal baclofen pump
- Critical: Never abruptly discontinue benzodiazepines — risk of status spasticus (life-threatening)
Immunotherapy
IVIg (Intravenous Immunoglobulin) — Strongest Evidence
Dalakas 2001 NEJM Trial: The landmark randomized, double-blind, placebo-controlled crossover study that established IVIg as the first evidence-based immunotherapy for SPS.
| Parameter | Details |
|---|---|
| Study design | Double-blind, placebo-controlled, crossover trial; 16 GAD65-positive patients; 3 months IVIg vs. placebo, 1-month washout, then crossover |
| Dose | 2 g/kg over 2–3 consecutive days, monthly |
| Primary outcomes | Stiffness index and heightened-sensitivity scores improved significantly with IVIg; scores worsened when IVIg was stopped and improved when re-initiated |
| Response rate | 11 of 14 completers (79%) showed clinical improvement — reduced stiffness, improved ambulation, some patients able to walk unassisted, resume work, or remain upright without fear of falling |
| GAD65 antibody effect | Significant reduction in anti-GAD65 titers with IVIg treatment |
Long-term IVIg maintenance (Dalakas 2022, Neurology Neuroimmunology & Neuroinflammation): In 36 GAD65-positive SPS patients on maintenance IVIg:
- 67% (24/36) had clinically meaningful response over a median 40-month (3.3 years) follow-up
- Responders showed improved gait, posture, balance, and decreased stiffness, spasms, and startle; some wheelchair-bound patients regained unassisted ambulation
- 29% experienced diminishing benefit over time due to disease progression
- Non-responders at 3 months remained non-responsive even with continued IVIg
- Maintenance protocol: 2 g/kg monthly (divided over 2–3 days), then assess with dependency trials — either reduce dose (2 → 1 g/kg) or extend interval (every 5–6 weeks) to find minimum effective maintenance regimen
Systematic review (Aryal 2022): Across 12 studies and 216 patients, 83% showed some improvement with IVIg, 15% showed no improvement, and 2% worsened.
Rituximab
Dalakas 2017 (Annals of Neurology): The only randomized, double-blind, placebo-controlled trial of rituximab in SPS.
| Parameter | Details |
|---|---|
| Study design | Double-blind, placebo-controlled; 24 GAD65-positive SPS patients; two bi-weekly infusions of rituximab (1 g each) vs. placebo |
| Primary outcome | Change in stiffness index at 6 months |
| Results | No statistically significant difference between rituximab and placebo in stiffness index or sensitivity scores at 3 or 6 months |
| Placebo effect | Quality of life scores improved significantly (p<0.01) at 3 months in both groups, indicating substantial placebo effect |
| Individual responders | Self-assessment showed 4 patients improved in each group; at 6 months, improvement persisted in 3 of 4 rituximab patients vs. 1 of 4 placebo patients, suggesting benefit in a subset |
| Interpretation | Possible explanations: strong placebo effect; insensitive outcome scales; rituximab may benefit only a small patient subset; B-cell depletion alone may be insufficient if long-lived plasma cells are the primary antibody source |
Rituximab systematic review (2025, Journal of Neurology): A comprehensive review of all published rituximab use in GAD65-positive SPS showed clinical improvement in a proportion of patients, but evidence is limited by small sample sizes and heterogeneous treatment protocols. Rituximab remains a reasonable option for patients refractory to IVIg.
Other Immunotherapies
| Agent | Evidence Level | Key Data |
|---|---|---|
| Plasma exchange (PLEX) | Case series | May provide short-term improvement; typically used as bridge therapy or in acute exacerbations; not practical for long-term maintenance |
| Corticosteroids | Case reports | Variable response; not recommended as monotherapy; some use as adjunct during acute exacerbations |
| Mycophenolate mofetil | Case series | Used as steroid-sparing agent; limited evidence |
| Azathioprine | Case reports | Occasional use as maintenance immunosuppressant; limited data |
| Tocilizumab (anti-IL-6R) | Case reports | Theoretical rationale via IL-6 role in B-cell activation; individual case reports of benefit; not established; also used for CRS management in context of CAR T-cell therapy |
| Subcutaneous immunoglobulin (SCIg) | Case series (2020–2021) | Feasible alternative to IVIg for maintenance therapy; allows home administration; 1-year follow-up data in small series show sustained benefit |
CAR T-Cell Therapy — Emerging Breakthrough
The most significant recent advance in SPS treatment is the application of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, targeting CD19-expressing B cells to eliminate the autoimmune source of pathogenic antibodies.
First-in-disease case report (PNAS, 2024):
- 69-year-old woman with 9 years of treatment-refractory SPS
- Received single infusion of miv-cel (KYV-101): autologous anti-CD19 CAR T cells, 1 × 108 cells, following lymphodepletion with fludarabine and cyclophosphamide
- Results: Walking speed increased >100%; daily walking distance improved from <50 m to >6 km within 3 months; benzodiazepine dose reduced by 40%
- Antibody response: Anti-GAD65 titers declined from 1:3,200 to 1:320 over 5 months
- Safety: Grade 2 CRS (fever, hypotension) by day 9, managed with dexamethasone and tocilizumab
KYSA-8 Registrational Phase 2 Trial (December 2025):
- Design: Open-label, multicenter, Phase 2 registrational study of miv-cel (formerly KYV-101) in treatment-refractory SPS
- Population: 26 patients with confirmed SPS
- Primary endpoint: Timed 25-Foot Walk (T25FW) at Week 16
- Results:
- Average 46% reduction in T25FW time vs. baseline (p = 0.0002)
- 81% of patients achieved a clinically meaningful reduction of at least 20%
- All key secondary endpoints met: improvement in disability scores, muscle stiffness, spasm triggers, and composite walking assessments
- Safety: Grade 3–4 neutropenia observed but manageable; no high-grade CRS or ICANS
- Regulatory path: Kyverna Therapeutics plans to file for FDA approval in first half of 2026 — this would be the first CAR T-cell therapy approved for an autoimmune disease
Immunotherapy Treatment Algorithm
- First-line immunotherapy: IVIg 2 g/kg monthly (strongest evidence; Dalakas 2001 NEJM trial); assess response at 3 months; if effective, continue with maintenance dose optimization
- Second-line: Rituximab (two 1 g infusions, 2 weeks apart) for IVIg non-responders or intolerant patients; may benefit a subset
- Refractory disease: Plasma exchange (bridge), combination immunotherapy (rituximab + IVIg), mycophenolate
- Treatment-refractory: CAR T-cell therapy (miv-cel / KYV-101) — pending regulatory approval (expected 2026); dramatic results in refractory patients
- Paraneoplastic SPS: Treat underlying malignancy first; immunotherapy may have limited benefit until tumor is controlled
Prognosis and Outcomes
- Natural history: Chronic, insidious onset with gradual progressive worsening over years to decades
- Disability: Significant functional impairment; only 19% of patients were able to work after 4 years of follow-up in one series; many patients eventually require ambulatory aids or wheelchairs
- Late-onset SPS (Dalakas 2023): In a series of late-onset cases, after median 3 years from symptom onset, 8 of 9 patients required an ambulatory device, and 2 required care facility residence
- Falls and injuries: Frequent; spasm-related falls are a major source of morbidity (fractures, head injuries)
- Quality of life: Markedly reduced due to chronic pain, immobility, anxiety, task-specific phobias, and social isolation
- Mortality: Generally low in classic SPS; death is rare and typically results from complications of immobility (DVT/PE, wound infections, pneumonia) rather than the disease itself; PERM carries higher mortality risk due to autonomic instability and respiratory failure
- Response to treatment: With IVIg, 67% show sustained benefit over ~3 years but ~29% experience diminishing returns; early treatment initiation may improve long-term outcomes
- Prognostic factors:
- Earlier diagnosis and treatment initiation correlate with better outcomes
- GAD65-positive patients generally respond better to immunotherapy than seronegative patients
- GlyR-positive PERM may respond well to aggressive immunotherapy despite severe presentation
- Paraneoplastic cases depend on successful oncologic treatment
Differential Diagnosis
| Condition | Distinguishing Features |
|---|---|
| Functional neurological disorder | Most common mimic (Chia 2023); Hoover sign, inconsistency, distractibility; normal EMG; negative serology; no improvement with IVIg |
| Myelopathy (multiple sclerosis, NMO, compressive) | Upper motor neuron signs, sensory level, bladder dysfunction; abnormal MRI spine; spasticity pattern differs from SPS rigidity |
| Ankylosing spondylitis | Inflammatory back pain; sacroiliac joint involvement; HLA-B27 positive; radiographic changes |
| Generalized anxiety disorder / conversion disorder | No true rigidity on examination; normal EMG; no response to benzodiazepines at SPS-level doses |
| Neuromyotonia (Isaacs syndrome) | Peripheral nerve hyperexcitability; myokymia, fasciculations, cramps; CASPR2/LGI1 antibodies; neuromyotonic discharges on EMG (different from CMUA) |
| Tetanus | Acute onset; trismus (lockjaw); wound history; Clostridium tetani toxin; risus sardonicus; no antibody association |
| Primary lateral sclerosis | Upper motor neuron degeneration; progressive spasticity; no episodic spasms; normal GAD65 antibodies |
| Parkinsonism | Bradykinesia, resting tremor, postural instability; rigidity is lead-pipe or cogwheel, not episodic; responds to levodopa |
References
- Dalakas MC. Stiff-person syndrome and GAD antibody-spectrum disorders: GABAergic neuronal excitability, immunopathogenesis and update on antibody therapies. Neurotherapeutics. 2022;19(3):832-847. doi: 10.1007/s13311-022-01235-w
- Dalakas MC. Stiff-person syndrome and related disorders — diagnosis, mechanisms and therapies. Nat Rev Neurol. 2024;20(10):587-601. doi: 10.1038/s41582-024-01012-3
- Dalakas MC. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med. 2001;345(26):1870-1876. doi: 10.1056/NEJMoa01167
- Dalakas MC, Rakocevic G, Dambrosia JM, et al. A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome. Ann Neurol. 2017;82(2):271-277. doi: 10.1002/ana.25002
- Dalakas MC. Long-term effectiveness of IVIg maintenance therapy in 36 patients with GAD antibody-positive stiff-person syndrome. Neurol Neuroimmunol Neuroinflamm. 2022;9(5):e200011. doi: 10.1212/NXI.0000000000200011
- Dalakas MC. Therapies in stiff-person syndrome: advances and future prospects based on disease pathophysiology. Neurol Neuroimmunol Neuroinflamm. 2023;10(3):e200109. doi: 10.1212/NXI.0000000000200109
- Dalakas MC, Yi J. Late-onset stiff-person syndrome: challenges in diagnosis and management. Ther Adv Neurol Disord. 2023;16:17562864231214315. doi: 10.1177/17562864231214315
- Chia NH, McKeon A, Dalakas MC, et al. Stiff person spectrum disorder diagnosis, misdiagnosis, and suggested diagnostic criteria. Ann Clin Transl Neurol. 2023;10(7):1083-1094. doi: 10.1002/acn3.51791
- Steinmetz A, Briani C, Geis C, et al. Stiff person spectrum disorders — an update and outlook on clinical, pathophysiological and treatment perspectives. Biomedicines. 2023;11(9):2500. doi: 10.3390/biomedicines11092500
- Thaler FS, Tani Y, Bhatt NK, et al. Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome. Proc Natl Acad Sci USA. 2024;121(28):e2403227121. doi: 10.1073/pnas.2403227121
- Kyverna Therapeutics. Positive topline data from registrational KYSA-8 trial of miv-cel (KYV-101) in stiff person syndrome. Press release, December 15, 2025.
- Yeh WZ, Dyck PJ, van den Berg LH, et al. Population-based study of the epidemiology of stiff person syndrome in a large Colorado-based health system. Neurology. 2024;103(12):e210078. doi: 10.1212/WNL.0000000000210078
- Matsui N, Tanaka K, Kinoshita M, et al. Prevalence, clinical profiles, and prognosis of stiff-person syndrome in a Japanese nationwide survey. Neurol Neuroimmunol Neuroinflamm. 2023;10(6):e200165. doi: 10.1212/NXI.0000000000200165
- Aryal S, Garg A, Engstrom JW. Intravenous immunoglobulin in the management and outcome of stiff-person syndrome: a systematic review. Clin Exp Neuroimmunol. 2022;13(4):254-262. doi: 10.1111/cen3.12713
- Martinez-Hernandez E, Dalakas MC. Rituximab in stiff-person syndrome with glutamic acid decarboxylase 65 autoantibody: a systematic review. J Neurol. 2025. doi: 10.1007/s00415-025-13157-2